Skip to content

Study · Animal study (in vivo) · rat · 2000

3 results

[Ultrastructural changes in the pancreas of rats with acute pancreatitis after semax administration].

Ivanov IuV

Eksperimental'naia i klinicheskaia farmakologiia1 Nov 2000

PMID11202510 (opens in a new tab)PepBankPUB-11202510
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, a single semax dose of 0.1 mg/kg into the pancreatic duct prevented increased necrosis of the acinar tissues.

    In plain wordsIn rats with pancreatitis, one dose of semax into the pancreatic duct prevented more death of pancreas tissue.

    Peptide
    Semax
    Outcome
    DecreaseNecrosis of acinar tissue
    Study

    ratsn: not reported in source

    Acute pancreatitis (AP) model
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.1 mg/kg · intrapancreatic duct · single administrationAs given in this study (rats).

    Source sentences

    Summary
    a single introduction of semax (0.1 mg/kg) into the pancreatic duct of rats with AP model prevents increased necrosis of the acinar tissues
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, semax inhibited purulent inflammation of the necrotised lobules.

    In plain wordsIn rats with pancreatitis, semax limited pus-forming inflammation in damaged pancreas lobules.

    Peptide
    Semax
    Outcome
    DecreasePurulent inflammation of necrotised lobules
    Study

    ratsn: not reported in source

    Acute pancreatitis (AP) model
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    0.1 mg/kg · intrapancreatic duct · single administrationAs given in this study (rats).

    Source sentences

    Summary
    a single introduction of semax (0.1 mg/kg) into the pancreatic duct of rats with AP model prevents increased necrosis of the acinar tissues and inhibits purulent inflammation of the necrotised lobules
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, semax induced sclerosis and atrophy of the necrotised lobules, so that large areas of the pancreas stayed intact.

    In plain wordsIn rats with pancreatitis, semax led damaged lobules to scar and shrink, which kept large pancreas areas intact.

    Peptide
    Semax
    Outcome
    IncreaseSclerosis and atrophy of necrotised lobules with preserved pancreas
    Study

    ratsn: not reported in source

    Acute pancreatitis (AP) model
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.1 mg/kg · intrapancreatic duct · single administrationAs given in this study (rats).

    Source sentences

    Summary
    a single introduction of semax (0.1 mg/kg) into the pancreatic duct of rats with AP model prevents increased necrosis of the acinar tissues and inhibits purulent inflammation of the necrotised lobules by inducing their sclerosis and atrophy, thus retaining large areas of the pancreas intact

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.